Hedge Fund - Broadfin Capital

Kevin Kotler's New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).

Kevin Kotler’s Broadfin Capital doesn’t want to hear any more excuses from the Board of Cardica, Inc. (NASDAQ:CRDC) for under-performance, it want change and that too immediately.

Canyon Capital Advisors, a fund led by Joshua Friedman and Mitchell Julis, disclosed boosting its position in DHT Holdings Inc (NYSE:DHT) to around 10.20 million shares from 4.96 million shares reported...

Last Friday, Kevin Kotler’s Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH).

According to a recent filing with the Securities and Exchange Commission, Altai Capital, run by Rishi Bajaj, Toby Symonds and Steve Tesoriere, has increased its holding of Servicesource International...

In a recent filing with the  Securities and Exchange Commission, Broadfin Capital has disclosed a letter sent to the Board of Directors of Cardica, Inc. (NASDAQ:CRDC).

Kevin Kotler and his fund, Broadfin Capital, have further boosted their holding of Cardica, Inc. (NASDAQ:CRDC) stock.

Kevin Kotler is bullish on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and has decided to boost his fund's investment in the stock.

In three recent filings,  Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc.